China SXT Pharmaceuticals (SXTC) Equity Average: 2018-2025
- China SXT Pharmaceuticals' Equity Average rose 23.16% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.8 million, marking a year-over-year increase of 23.16%. This contributed to the annual value of $14.7 million for FY2025, which is 2.62% up from last year.
- Latest data reveals that China SXT Pharmaceuticals reported Equity Average of $17.8 million as of Q3 2025, which was up 17.06% from $15.2 million recorded in Q1 2025.
- China SXT Pharmaceuticals' Equity Average's 5-year high stood at $17.8 million during Q3 2025, with a 5-year trough of $9.5 million in Q1 2024.
- Moreover, its 3-year median value for Equity Average was $14.6 million (2023), whereas its average is $13.6 million.
- In the last 5 years, China SXT Pharmaceuticals' Equity Average surged by 65.70% in 2021 and then plummeted by 36.87% in 2023.
- China SXT Pharmaceuticals' Equity Average (Quarterly) stood at $14.9 million in 2021, then rose by 5.25% to $15.7 million in 2022, then crashed by 36.87% to $9.9 million in 2023, then skyrocketed by 46.53% to $14.5 million in 2024, then climbed by 23.16% to $17.8 million in 2025.
- Its Equity Average was $17.8 million in Q3 2025, compared to $15.2 million in Q1 2025 and $14.5 million in Q3 2024.
